SYNLAB AG Logo

SYNLAB AG

SYAB.DE

(1.2)
Stock Price

11,06 EUR

4.67% ROA

3.79% ROE

27.2x PER

Market Cap.

2.430.711.588,00 EUR

44.78% DER

2.98% Yield

3.42% NPM

SYNLAB AG Stock Analysis

SYNLAB AG Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

SYNLAB AG Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE in an average range (10.15%) suggests satisfactory profitability and decent utilization of shareholders' equity.

2 ROA

The stock's ROA (3.17%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

3 PBV

The stock's PBV ratio (1.06x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

4 DER

The stock has a reasonable amount of debt compared to its ownership (86%), suggesting a balanced financial position and a moderate level of risk.

5 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is undervalued (1.492), making it an appealing investment prospect with its intrinsic value surpassing the current market price.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

10 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

11 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

SYNLAB AG Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

SYNLAB AG Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

SYNLAB AG Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

SYNLAB AG Revenue
Year Revenue Growth
2015 844.705.855
2016 1.570.100.000 46.2%
2017 1.816.645.000 13.57%
2018 1.807.873.000 -0.49%
2019 1.906.070.000 5.15%
2020 2.621.184.000 27.28%
2021 3.764.916.000 30.38%
2022 3.250.521.000 -15.83%
2023 2.468.632.000 -31.67%
2023 2.635.163.000 6.32%
2024 2.729.684.000 3.46%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

SYNLAB AG Research and Development Expenses
Year Research and Development Expenses Growth
2015 0
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

SYNLAB AG General and Administrative Expenses
Year General and Administrative Expenses Growth
2015 376.748.634
2016 0 0%
2017 823.055.000 100%
2018 736.479.000 -11.76%
2019 776.060.000 5.1%
2020 39.638.000 -1857.87%
2021 52.858.000 25.01%
2022 75.840.000 30.3%
2023 0 0%
2023 150.154.000 100%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

SYNLAB AG EBITDA
Year EBITDA Growth
2015 134.994.880
2016 280.195.000 51.82%
2017 295.304.000 5.12%
2018 260.329.000 -13.43%
2019 264.058.000 1.41%
2020 778.618.000 66.09%
2021 1.197.384.000 34.97%
2022 966.997.000 -23.82%
2023 388.568.000 -148.86%
2023 411.429.000 5.56%
2024 491.464.000 16.29%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

SYNLAB AG Gross Profit
Year Gross Profit Growth
2015 651.198.966
2016 1.218.761.000 46.57%
2017 1.422.567.000 14.33%
2018 1.395.360.000 -1.95%
2019 1.469.065.000 5.02%
2020 1.936.667.000 24.14%
2021 2.822.482.000 31.38%
2022 2.473.605.000 -14.1%
2023 1.910.128.000 -29.5%
2023 569.890.000 -235.17%
2024 681.092.000 16.33%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

SYNLAB AG Net Profit
Year Net Profit Growth
2015 -168.881.171
2016 -230.401.000 26.7%
2017 -165.574.000 -39.15%
2018 -51.268.000 -222.96%
2019 -121.867.000 57.93%
2020 37.941.000 421.2%
2021 624.763.000 93.93%
2022 150.697.000 -314.58%
2023 517.896.000 70.9%
2023 92.274.000 -461.26%
2024 99.908.000 7.64%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

SYNLAB AG Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2015 0
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 3 100%
2022 1 0%
2023 2 100%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

SYNLAB AG Free Cashflow
Year Free Cashflow Growth
2015 -36.454.292
2016 155.675.000 123.42%
2017 135.597.000 -14.81%
2018 253.105.000 46.43%
2019 288.996.000 12.42%
2020 425.502.000 32.08%
2021 867.221.000 50.93%
2022 471.354.000 -83.99%
2023 150.170.000 -213.88%
2023 58.628.000 -156.14%
2024 76.757.000 23.62%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

SYNLAB AG Operating Cashflow
Year Operating Cashflow Growth
2015 7.126.287
2016 231.581.000 96.92%
2017 212.607.000 -8.92%
2018 338.612.000 37.21%
2019 359.750.000 5.88%
2020 520.414.000 30.87%
2021 1.011.703.000 48.56%
2022 629.625.000 -60.68%
2023 290.402.000 -116.81%
2023 93.878.000 -209.34%
2024 100.016.000 6.14%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

SYNLAB AG Capital Expenditure
Year Capital Expenditure Growth
2015 43.580.579
2016 75.906.000 42.59%
2017 77.010.000 1.43%
2018 85.507.000 9.94%
2019 70.754.000 -20.85%
2020 94.912.000 25.45%
2021 144.482.000 34.31%
2022 158.271.000 8.71%
2023 140.232.000 -12.86%
2023 35.250.000 -297.82%
2024 23.259.000 -51.55%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

SYNLAB AG Equity
Year Equity Growth
2015 -114.089.000
2016 -339.016.000 66.35%
2017 1.088.467.000 131.15%
2018 1.047.769.000 -3.88%
2019 947.461.000 -10.59%
2020 1.203.552.000 21.28%
2021 2.255.699.000 46.64%
2022 -595.418.000 478.84%
2023 2.338.231.000 125.46%
2023 2.417.370.000 3.27%
2024 2.370.028.000 -2%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

SYNLAB AG Assets
Year Assets Growth
2015 3.616.316.000
2016 3.885.557.000 6.93%
2017 4.324.971.000 10.16%
2018 4.642.758.000 6.84%
2019 4.785.163.000 2.98%
2020 5.283.189.000 9.43%
2021 5.425.945.000 2.63%
2022 5.381.114.000 -0.83%
2023 4.663.266.000 -15.39%
2023 4.989.737.000 6.54%
2024 4.707.237.000 -6%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

SYNLAB AG Liabilities
Year Liabilities Growth
2015 3.730.405.000
2016 4.224.573.000 11.7%
2017 3.236.504.000 -30.53%
2018 3.594.989.000 9.97%
2019 3.837.702.000 6.32%
2020 4.079.637.000 5.93%
2021 3.170.246.000 -28.69%
2022 3.047.873.000 -4.02%
2023 2.325.035.000 -31.09%
2023 2.572.367.000 9.61%
2024 2.337.209.000 -10.06%

SYNLAB AG Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
11.9
Net Income per Share
0.41
Price to Earning Ratio
27.2x
Price To Sales Ratio
0.93x
POCF Ratio
6.34
PFCF Ratio
9.88
Price to Book Ratio
1.02
EV to Sales
1.42
EV Over EBITDA
8.09
EV to Operating CashFlow
9.69
EV to FreeCashFlow
15.1
Earnings Yield
0.04
FreeCashFlow Yield
0.1
Market Cap
2,43 Bil.
Enterprise Value
3,72 Bil.
Graham Number
9.94
Graham NetNet
-7.63

Income Statement Metrics

Net Income per Share
0.41
Income Quality
-777.67
ROE
0.04
Return On Assets
0.02
Return On Capital Employed
0.03
Net Income per EBT
0.64
EBT Per Ebit
1.02
Ebit per Revenue
0.05
Effective Tax Rate
0.36

Margins

Sales, General, & Administrative to Revenue
0.04
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.5
Operating Profit Margin
0.05
Pretax Profit Margin
0.05
Net Profit Margin
0.03

Dividends

Dividend Yield
0.03
Dividend Yield %
2.98
Payout Ratio
0
Dividend Per Share
0.33

Operating Metrics

Operating Cashflow per Share
1.74
Free CashFlow per Share
1.12
Capex to Operating CashFlow
0.36
Capex to Revenue
0.05
Capex to Depreciation
0.47
Return on Invested Capital
0.03
Return on Tangible Assets
0.05
Days Sales Outstanding
61.08
Days Payables Outstanding
80.4
Days of Inventory on Hand
17.49
Receivables Turnover
5.98
Payables Turnover
4.54
Inventory Turnover
20.87
Capex per Share
0.62

Balance Sheet

Cash per Share
1,37
Book Value per Share
10,78
Tangible Book Value per Share
-1.93
Shareholders Equity per Share
10.79
Interest Debt per Share
5.34
Debt to Equity
0.45
Debt to Assets
0.23
Net Debt to EBITDA
2.8
Current Ratio
1.24
Tangible Asset Value
-0,42 Bil.
Net Current Asset Value
-1,48 Bil.
Invested Capital
3895601000
Working Capital
0,17 Bil.
Intangibles to Total Assets
0.59
Average Receivables
0,44 Bil.
Average Payables
0,29 Bil.
Average Inventory
63962000
Debt to Market Cap
0.44

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

SYNLAB AG Dividends
Year Dividends Growth
2022 0
2023 0 0%
2024 0 0%

SYNLAB AG Profile

About SYNLAB AG

SYNLAB AG provides clinical laboratory and medical diagnostic services for insurance companies, hospitals, pharmacies, national health organizations, practicing doctors, clinics, patients, governments, and corporations primarily in Europe. The company offers Coronavirus tests, and medical and veterinary diagnostics services. It operates through approximately 500 laboratories and 1,800 blood collection points in 36 countries in four continents. The company was founded in 1998 and is headquartered in Munich, Germany.

CEO
Mr. Mathieu Floreani
Employee
27.000
Address
Moosacher Straße 88
Munich, 80809

SYNLAB AG Executives & BODs

SYNLAB AG Executives & BODs
# Name Age
1 Alexander Hagen
Group Head of Commercial & Marketing
70
2 Mr. Luis Vieira
Group Chief Strategy Officer
70
3 Dr. Anna Niedl
Head of Investor Relations
70
4 Dr. Santiago Valor
Chief Medical Officer
70
5 Mr. Robert Steinwander
Group Chief Operating Officer
70
6 Ms. Kimberly Urdahl
Group General Counsel & Group Chief Compliance Officer
70
7 Mr. Sami Badarani
Chief Financial Officer & Member of Management Board
70
8 Ms. Catharina Monster
Group Chief Human Resources Officer
70
9 Dr. Bartholomäus Wimmer
Founder & Independent Member of the Supervisory Board
70
10 Mr. Mathieu Floreani
Chairman of the Management Board & Chief Executive Officer
70

SYNLAB AG Competitors

SUSE S.A. Logo
SUSE S.A.

SUSE.DE

(1.5)
Dermapharm Holding SE Logo
Dermapharm Holding SE

DMP.DE

(2.8)
Hensoldt AG Logo
Hensoldt AG

HAG.DE

(1.5)
Traton SE Logo
Traton SE

8TRA.DE

(3.2)